Questions and Answers
What is the indication and usage for Myrbetriq monotherapy?
Myrbetriq is a beta 3 adrenergic agonist indicated for the treatment of OAB with symptoms of urge urinary incontinence, urgency, and urinary frequency.
What is the indication and usage for Myrbetriq combination therapy?
Myrbetriq in combination with the muscarinic antagonist solifenacin succinate is indicated for the treatment of OAB with symptoms of urge urinary incontinence, urgency, and urinary frequency.
What is the dosing of Myrbetriq monotherapy?
Recommended starting dose of Myrbetriq is 25mg once daily with or without food, which may be increased to 50mg once daily based on efficacy and tolerability.
What is the dosing of Myrbetriq in combination with VESIcare?
Signup and view all the answers
In what populations should the daily dose of Myrbetriq not exceed 25mg?
Signup and view all the answers
Describe both doses of Myrbetriq (color and strength).
Signup and view all the answers
Describe the contraindications of Myrbetriq.
Signup and view all the answers
Describe the warnings and precautions of Myrbetriq.
Signup and view all the answers
Describe the warnings and precautions with Myrbetriq monotherapy.
Signup and view all the answers
Study Notes
Myrbetriq Overview
- Myrbetriq is a beta 3 adrenergic agonist used for treating overactive bladder (OAB) symptoms, including urge urinary incontinence, urgency, and urinary frequency.
- Can be used as monotherapy or in combination with solifenacin succinate.
Dosing Information
- Monotherapy: Starting dose is 25mg once daily; may increase to 50mg once daily based on efficacy and tolerability. Effective within 8 weeks.
- Combination Therapy: 25mg Myrbetriq and 5mg solifenacin daily; can increase Myrbetriq to 50mg after 4 to 8 weeks depending on patient response.
- Both can be taken with or without food.
Patient Populations
- Maximum daily dose of 25mg for patients with severe renal impairment (creatinine clearance <30) or moderate hepatic impairment (Child Pugh Class B).
- Not recommended for severe hepatic impairment (Child Pugh Class C), End Stage Renal Disease, severe uncontrolled hypertension (>180/110), or patients under 18.
Dosage Appearance
- 25mg: Oval, brown, film-coated tablet, marked with Astellas logo and "325".
- 50mg: Oval, yellow, film-coated tablet, marked with Astellas logo and "355".
Contraindications
- Myrbetriq should not be used in patients with known hypersensitivity to mirabegron or any tablet components.
Warnings and Precautions
- Blood Pressure: Myrbetriq can raise blood pressure; monitor periodically, especially in hypertensive patients. Should not be used in severe uncontrolled hypertension.
- Reported mild increases in blood pressure were observed in clinical trials.
- Urinary Retention: Caution advised in patients with bladder outlet obstruction. Postmarketing reports of urinary retention exist.
- CYP2D6 Inhibition: Myrbetriq is a moderate CYP2D6 inhibitor. Concomitant use with CYP2D6 substrates may require monitoring and dose adjustments.
- Angioedema Risk: Angioedema of the face, lips, tongue, or larynx may occur. Discontinue Myrbetriq immediately and take necessary measures for airway safety.
Additional Considerations
- Worsening pre-existing hypertension was infrequent in clinical trial patients receiving Myrbetriq.
- Monitoring for adverse effects is critical, particularly in patients with a history of hypertension or urinary obstruction.
Studying That Suits You
Use AI to generate personalized quizzes and flashcards to suit your learning preferences.
Description
This quiz covers the essential information on Myrbetriq, a medication used for treating overactive bladder symptoms. Learn about its dosing guidelines, patient populations, and how it can be used as monotherapy or in combination with solifenacin. Test your knowledge on the safe administration and indications for this medication.
